4baseCare closes Series B at ₹128 crore as growX Ventures, Infosys lead top-up
What's the deal? Precision oncology startup 4baseCare has closed its Series B round at ₹128 crore (about $15 million) after raising an additional ₹38 crore in a top-up led by growX VenturesDealroom has a profile for this one. Try Dealroom → and InfosysDealroom has a profile for this one. Try Dealroom →, with participation from existing investors. The Bengaluru-based company had earlier raised ₹90 crore in the round's first close, and plans to use the fresh capital to expand its genomics laboratory network globally and scale its AI-powered oncology platform, OncoTwin.
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare develops genomics-driven cancer diagnostics and clinical decision support tools. It operates labs in India, Dubai, Nepal, and the Philippines, and plans to expand into 8–10 additional countries over the next 12–18 months.
"We want precision oncology globally to be more inclusive," said Goswami, the company's chief executive. "Most genomic datasets, drug discovery, and clinical trials are still heavily concentrated in the US and Europe."
Why now? India sees nearly 1.5 million new cancer cases annually, with around 70% of patients diagnosed at advanced stages where targeted therapy and immunotherapy become critical. Genomic testing helps identify molecular changes in tumours and maps patients to more personalised treatments.
Globally, precision oncology has emerged as one of the fastest-growing segments in healthcare AI. Yet most genomic datasets remain dominated by Caucasian populations, limiting treatment insights for emerging markets — a gap 4baseCare aims to fill across India, the Middle East, southeast Asia, and Latin America.
The startup is also decentralising genomic testing in India. It partnered with Max HealthcareDealroom has a profile for this one. Try Dealroom →, AIIMS Jammu, and Shankara Hospital to set up in-hospital genomics labs rather than shipping samples to a central facility in Bengaluru.
"That improves turnaround time, improves research collaboration, and makes advanced cancer diagnostics more accessible," Goswami said.
What could go wrong? Scaling genomics labs across multiple countries brings regulatory complexity, quality-control challenges, and significant operational costs. The company currently conducts around 1,500 genomic tests per month and aims to reach 8,000–10,000 — a sixfold increase that will test its infrastructure and workforce.
Competing against well-funded Western genomics firms with established datasets and hospital relationships is another hurdle. Convincing healthcare systems in emerging markets to adopt and reimburse genomic testing at scale remains an open question.
The signal: Having a corporate investor like Infosys — which typically backs enterprise technology rather than biotech — co-lead a round for 4baseCare underscores how precision oncology is increasingly viewed as an AI and data infrastructure play, not just a healthcare one. The company's bet on building population-relevant datasets for under-served markets could prove strategically valuable as Western genomics firms look to expand beyond Caucasian-dominated databases, positioning it as both a diagnostics provider and a data partner.
Read more: The Economic Times
